Key Highlights

  • Bio-Rad Laboratories (NYSE:BIO) reported USD 17.02 of Diluted Earnings per Share against a USD 12.70 loss a year earlier, with a USD 588.2 million fair-value gain doing most of the work.
  • PacBio (NASDAQ:PACB) brought in USD 40.6 million of Revenue and lost USD 0.12 per share, while cash and investments slipped to USD 199.4 million from USD 298.7 million.
  • Myriad Genetics (NASDAQ:MYGN) agreed to sell its Prenatal Health unit, collecting USD 210 million in cash plus inventory value, and expects to finish by early 2027.
  • Veracyte (NASDAQ:VCYT) lifted revenue 15% to USD 151.8 million and approved a repurchase of up to USD 100 million, even as its full-year revenue range was trimmed to USD 590 million to USD 593 million.

Bio-Rad Laboratories (NYSE:BIO): How a Sartorius Stake Revaluation Reshaped the Quarterly EPS

Bio-Rad Laboratories (NYSE:BIO) submitted its Quarterly Report on November 4, 2026. Attributable Net Income reached USD 458.6 million, equal to USD 17.02 on a diluted basis, while the year-earlier period showed a USD 341.9 million loss, or USD 12.70 a share. Nearly all of that swing sits outside core operations, since the company booked a USD 588.2 million rise in the Fair Value of Equity holdings and a Loan receivable. Of that amount, USD 583.2 million was a holding gain on its Sartorius investment, which had produced a USD 505.1 million markdown a year before. Underlying sales moved far less, edging up 0.5% to USD 656.4 million. Clinical Diagnostics grew 2.7%, whereas Life Science slipped 2.8% on weaker process chromatography orders and softer academic demand. Gross Margin fell to 50.1% from 52.6%, with higher restructuring charges identified as the cause. A plan launched July 31, 2026 could cost between USD 80 million and USD 90 million before tax, and USD 77.6 million landed in this quarter.

PacBio (NASDAQ:PACB): Instrument Sales Lift Revenue as Cash Declines Over the Year

PacBio (NASDAQ:PACB) announced its third-quarter 2026 figures on November 4, 2026. Revenue reached USD 40.6 million, up from USD 38.4 million, which works out to growth of about 5.7% by our own calculation. Instruments contributed USD 13.2 million, consumables USD 20.8 million, and service plus other sales USD 6.6 million. The HiFi long-read sequencing maker installed 15 Revio systems and 35 Vega units during the period. The GAAP loss narrowed to USD 37.8 million, or USD 0.12 a share, from USD 38.0 million, or USD 0.13. Non-GAAP gross margin, however, dropped to 36% from 42%, a decline management linked to pricier memory components and transition costs for Vega production. Cash, equivalents and investments ended at USD 199.4 million, roughly USD 99.3 million below the year-earlier balance by our arithmetic. Looking ahead, the 2026 sales forecast now sits between USD 155 million and USD 160 million, although the release supplied no earlier figure. The chief financial officer, Jim Gibson, has stepped down, and chief executive Mark Van Oene is serving as interim CFO while a search proceeds.

Myriad Genetics (NASDAQ:MYGN): A USD 210 Million Prenatal Divestiture Alongside a Wider Loss

Myriad Genetics (NASDAQ:MYGN) sells molecular diagnostics across prenatal, cancer care and mental health. Its third-quarter 2026 revenue came to USD 202.7 million, slightly under the USD 205.7 million of a year earlier but higher than the prior quarter. The net loss expanded to USD 43.9 million, or USD 0.46 a share, from USD 27.4 million, or USD 0.29. On October 19, 2026 the company signed an agreement to hand its Prenatal Health Business to a national laboratory operator for USD 210 million in cash, plus the value of inventory at closing. Completion is anticipated by early 2027, subject to regulatory clearances and customary conditions. Prenatal generated USD 39.3 million in the quarter, a 12% decline, while cancer care and mental health products brought in USD 163.4 million, up 1%. Management argues the transaction should add to revenue growth and profitability and bolster the balance sheet. Full-year revenue guidance now stands at USD 780 million to USD 790 million with the midpoint lifted, though the prior range was not included in the release. Liquidity stood at USD 107.1 million in cash, while long-term borrowings reached USD 121.1 million; the release says nothing about the share price response.

Veracyte (NASDAQ:VCYT): A USD 100 Million Repurchase Authority Arrives With a Trimmed Revenue Range

Veracyte (NASDAQ:VCYT) reported third-quarter results on November 4, 2026. Total revenue climbed 15% to USD 151.8 million, with Decipher Prostate rising 12% to USD 92.3 million and Afirma gaining 19% to USD 51.5 million. The chief executive acknowledged that Decipher Prostate volumes came in under plan. GAAP net income reached USD 31.5 million, or USD 0.38 per diluted share, while adjusted EBITDA of USD 41.2 million represented 27.2% of revenue. The directors approved repurchases of up to USD 100 million over a 12-month window, funded from existing cash and carrying no obligation to buy. In the same release, the full-year total revenue forecast was trimmed at the top, moving to USD 593 million from USD 596 million, while the floor stays at USD 590 million. Testing revenue guidance fell too, to a USD 571 million to USD 573 million band from USD 576 million to USD 582 million. The filing offers no explanation of the board's intent. Cash and short-term investments stood at USD 370.5 million on September 30, 2026.

Where Things Stand

The Sartorius revaluation, not the operating business, carried Bio-Rad Laboratories (NYSE:BIO) to a profit, and sales grew only 0.5%, so that gain could reverse in a later quarter. PacBio (NASDAQ:PACB) cut its loss per share but used up roughly USD 99.3 million of cash over twelve months by our reckoning. Myriad Genetics (NASDAQ:MYGN) is shedding a segment while its loss expanded. Veracyte (NASDAQ:VCYT) pairs a buyback with a narrower revenue outlook and softer Decipher volume. Next markers are Bio-Rad restructuring savings, the PacBio finance chief search, approvals needed for Myriad's early 2027 closing and Decipher Prostate volumes. This article restates reported figures and offers no forecast or recommendation.